Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Vir Biotechnology, Inc. logoVir Biotechnology, Inc.

VIR · Nasdaq · USD · Market cap $1.7B · 367 employees

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.

FAIL · Does not pass the screen
8.39 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price8.39 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.51x the price, above our 2.00x limit.
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 1.29)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Markup ?
Screened · screened 2026-11-20
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.29, read 2026-11-19
  • Ethical does not pass the values gate
Price8.39 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-11Read Markup13.15-36.2% to today Accumulation gives way to Markup after a 16% rise in 10 days
2026-11-01Read Accumulation11.30-25.8% to today Markdown gives way to Accumulation after an 8% rise in 7 days
2026-10-25Read Markdown10.43-19.6% to today ✓Accumulation gives way to Markdown after a 10% slide in 2 weeks
2026-10-11Read Accumulation11.60-27.7% to today Markdown gives way to Accumulation after a 9% rise in 9 days

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Vir Biotechnology, Inc. holds its Markup at $8.39. Elevated stress, defensive posture warranted, held for 3 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateElevated stress, defensive posture warranted, held for 3 days
Price at the screen$8.39
ValuationN/A trailing · -3.87 forward price to earnings
Values screenFAIL · score 70.0
Beta1.74
The Workings

Five Screens: VIR's Results

FAIL. Revenue purity

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 9.76% Below 33% Pass
Interest-bearing cash 31.37% Below 33% Pass
Receivables 23.15% Below 49% Pass
Revenue purity 60.49% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Vir Biotechnology, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 60% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when VIR's ethical verdict changes

Today VIR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.51x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
17.00Street low 23.00Street average 30.00Street high 8.39Price

Street: 8 covering, consensus Strong Buy. Average target +174%.

Chart
The Business, in Plain Words

Clinical stage bets rarely deliver on paper promise

A company whose entire value sits in unproven drugs for infectious diseases is like funding a race car that has never left the workshop. Vir Biotechnology trades at half our calculated fair value with a forward multiple that reflects deep losses, yet the opportunity rating stays at none because clinical pipelines this early carry failure rates that wipe out capital fast.

The business shows zero profit margins and a negative return on equity of 48 percent, which is normal for a firm still burning cash on trials. Even with an ethical screen that passes cleanly and analyst targets clustered around 21 dollars, the absence of any moat or commercial product leaves the upside looking more like a lottery ticket than a repeatable business.

Risk sits in the binary outcomes of late stage data and dilution that often follows missed milestones. Currency or market swings matter less here than the simple fact that most such pipelines never reach paying customers. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-3.9x
EPS, trailing-1.18
EPS, forward-2.39
Profit margin-61.0%currently unprofitable
Return on equity-21.8%not currently earning a positive return on equity
FCF yield-4.75%
Debt to equity0.10minimal debt: a conservative balance sheet
Current ratio6.30comfortably covers its short-term bills
Beta1.74much more volatile than the market
Short interest, float0.10%
52-week range5.32 - 14.38
Market cap$1.7B
Employees367

VIR-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $9.15 -1.1% Entry 20
2026-11-18 Markup $9.25 -29.7% Entry 19
2026-11-11 Markup · changed $13.15 +17.2% Entry 18

The framework has shifted from accumulation to markup since the last review.

2026-11-04 Accumulation $11.22 -0.7% Entry 17
2026-11-03 Accumulation $11.30 +0.0% Entry 16
2026-11-02 Accumulation $11.30 +0.0% Entry 15
2026-11-01 Accumulation · changed $11.30 +6.9% Entry 14

The framework has shifted from markdown to accumulation since the last review.

2026-10-31 Markdown $10.57 +0.0% Entry 13
2026-10-30 Markdown $10.57 +0.0% Entry 12
2026-10-29 Markdown $10.57 +1.3% Entry 11

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on VIR

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in VIR's Space

Screened names in the same industry · explore each on its own page.

The Political Ledger · Congressional Disclosures
Disclosures naming VIR
DatePoliticianPartyTypeAmount
2026-10-15 Mike Kelly Republican sell 50K–100K
2026-10-15 Ro Khanna Democrat buy 50K–100K
2026-10-15 Mike Kelly Republican sell 50K–100K
2026-10-13 Ro Khanna Democrat buy 50K–100K
2026-09-23 Kevin Hern Republican sell 15K–50K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $9.29 -11.2% · $888 -11.2%
2 months $9.50 -13.2% · $868 -13.2%
3 months $9.48 -13.0% · $870 -13.0%
6 months $6.63 +24.4% · $1,244 +24.4%
1 year $5.42 +52.2% · $1,522 +52.2%
2 years $11.21 -26.4% · $736 -26.4%
3 years $25.43 -67.6% · $324 -67.6%
5 years $45.53 -81.9% · $181 -81.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever VIR does next, these words stay.

Vir Biotechnology, Inc. · VIR · Markup · $8.39
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.